REPL
Price
$3.15
Change
+$0.05 (+1.61%)
Updated
Jul 25 closing price
Capitalization
242.82M
4 days until earnings call
ZBIO
Price
$15.66
Change
-$0.66 (-4.04%)
Updated
Jul 25 closing price
Capitalization
655.12M
38 days until earnings call
Interact to see
Advertisement

REPL vs ZBIO

Header iconREPL vs ZBIO Comparison
Open Charts REPL vs ZBIOBanner chart's image
Replimune Group
Price$3.15
Change+$0.05 (+1.61%)
Volume$5.57M
Capitalization242.82M
Zenas Biopharma
Price$15.66
Change-$0.66 (-4.04%)
Volume$164.37K
Capitalization655.12M
REPL vs ZBIO Comparison Chart in %
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REPL vs. ZBIO commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Buy and ZBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (REPL: $3.15 vs. ZBIO: $15.66)
Brand notoriety: REPL and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 114% vs. ZBIO: 91%
Market capitalization -- REPL: $242.82M vs. ZBIO: $655.12M
REPL [@Biotechnology] is valued at $242.82M. ZBIO’s [@Biotechnology] market capitalization is $655.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, ZBIO is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 5 TA indicator(s) are bullish while ZBIO’s TA Score has 5 bullish TA indicator(s).

  • REPL’s TA Score: 5 bullish, 5 bearish.
  • ZBIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than REPL.

Price Growth

REPL (@Biotechnology) experienced а -73.95% price change this week, while ZBIO (@Biotechnology) price change was +14.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

ZBIO is expected to report earnings on Sep 03, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($655M) has a higher market cap than REPL($243M). ZBIO YTD gains are higher at: 91.209 vs. REPL (-73.988). ZBIO has higher annual earnings (EBITDA): -173.51M vs. REPL (-235.43M). REPL has more cash in the bank: 484M vs. ZBIO (312M). ZBIO has less debt than REPL: ZBIO (1.23M) vs REPL (76.2M). ZBIO has higher revenues than REPL: ZBIO (15M) vs REPL (0).
REPLZBIOREPL / ZBIO
Capitalization243M655M37%
EBITDA-235.43M-173.51M136%
Gain YTD-73.98891.209-81%
P/E RatioN/AN/A-
Revenue015M-
Total Cash484M312M155%
Total Debt76.2M1.23M6,220%
FUNDAMENTALS RATINGS
REPL: Fundamental Ratings
REPL
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
98
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
REPLZBIO
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 5 days ago
90%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 6 days ago
77%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSGSX15.810.14
+0.89%
MassMutual Small Cap Gr Eq R5
RCGTX15.360.09
+0.59%
Virtus Zevenbergen Technology C
LAFCX20.220.10
+0.50%
Lord Abbett Affiliated C
REUYX46.880.14
+0.30%
Russell Sustnbl Aware Eq Y
MRJIX10.94N/A
N/A
Morgan Stanley Multi-Asset Real Return I

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+1.61%
IMNN - REPL
62%
Loosely correlated
-7.24%
SNDX - REPL
49%
Loosely correlated
-3.60%
KYMR - REPL
46%
Loosely correlated
-0.13%
CGON - REPL
45%
Loosely correlated
-0.15%
ERAS - REPL
44%
Loosely correlated
+1.75%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with REPL. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
-4.04%
REPL - ZBIO
40%
Loosely correlated
+1.61%
NTLA - ZBIO
34%
Loosely correlated
+6.38%
SNDX - ZBIO
34%
Loosely correlated
-3.60%
OCUL - ZBIO
33%
Poorly correlated
+2.43%
KURA - ZBIO
33%
Poorly correlated
N/A
More